Literature DB >> 2280020

Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1.

J Boulanger1, M Petric, C Lingwood, H Law, M Roscoe, M Karmali.   

Abstract

The NeutRELISA, a modification of the receptor enzyme-linked immunosorbent assay developed for the detection of verocytotoxin 1 (VT1) which permits the rapid detection of neutralizing antibodies (NAb) against this toxin, has been performed. A standard concentration of VT1 was preincubated with VT-immune or nonimmune rabbit serum. The serum-toxin mixtures were then added to microtiter plates coated with deacylated globotriosyl ceramide (lyso-Gb3). The reduction of VT1 binding to lyso-Gb3 in the immune serum-toxin mixtures compared with the VT1-Gb3 binding in the nonimmune serum-toxin mixtures was detected by using mouse monoclonal antibody to VT1. After standardization of the NeutRELISA with rabbit sera, 57 human control serum samples were tested to establish a cutoff value below which NeutRELISA results would be considered positive. Thirty-three single serum samples known to demonstrate NAb to VT1 by biological assay reproducibly demonstrated VT1 NAb when tested by the NeutRELISA. There was a close correlation between the biological VT1 neutralization assay and the NeutRELISA. This assay offers a practical, rapid, and reliable approach for the detection of NAb to VT1 and other verocytotoxins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280020      PMCID: PMC268288          DOI: 10.1128/jcm.28.12.2830-2833.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  8 in total

1.  Sensitive receptor-specified enzyme-linked immunosorbent assay for Escherichia coli verocytotoxin.

Authors:  M Basta; M Karmali; C Lingwood
Journal:  J Clin Microbiol       Date:  1989-07       Impact factor: 5.948

2.  Epidemiology of sporadic diarrhea due to verocytotoxin-producing Escherichia coli: a two-year prospective study.

Authors:  C H Pai; N Ahmed; H Lior; W M Johnson; H V Sims; D E Woods
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

3.  Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli.

Authors:  N A Strockbine; L R Marques; R K Holmes; A D O'Brien
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

4.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

5.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

Review 6.  Infection by verocytotoxin-producing Escherichia coli.

Authors:  M A Karmali
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

7.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

8.  Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.

Authors:  A Cohen; V Madrid-Marina; Z Estrov; M H Freedman; C A Lingwood; H M Dosch
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

  8 in total
  8 in total

1.  Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.

Authors:  M Bielaszewska; I Clarke; M A Karmali; M Petric
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

2.  Effect of globotriaosyl ceramide fatty acid alpha-hydroxylation on the binding by verotoxin 1 and verotoxin 2.

Authors:  Beth Binnington; Daniel Lingwood; Anita Nutikka; Clifford A Lingwood
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

3.  Brief heat shock treatment induces a long-lasting alteration in the glycolipid receptor binding specificity and growth rate of Haemophilus influenzae.

Authors:  E Hartmann; C Lingwood
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

4.  Expression of A and B subunits of Shiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology.

Authors:  F Gunzer; H Karch
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

5.  Experimental verocytotoxemia in rabbits.

Authors:  S E Richardson; T A Rotman; V Jay; C R Smith; L E Becker; M Petric; N F Olivieri; M A Karmali
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

6.  Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1.

Authors:  M A Karmali; M Petric; M Winkler; M Bielaszewska; J Brunton; N van de Kar; T Morooka; G B Nair; S E Richardson; G S Arbus
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

7.  Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.

Authors:  Tom G Obrig
Journal:  Toxins (Basel)       Date:  2010-12-02       Impact factor: 4.546

8.  Shiga toxin binding to glycolipids and glycans.

Authors:  Karen M Gallegos; Deborah G Conrady; Sayali S Karve; Thusitha S Gunasekera; Andrew B Herr; Alison A Weiss
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.